{"commentary":{"count":153,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":71,"podcast":55,"x_thread":26,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03742102\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"BEGONIA","nct_id":"NCT03742102","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=begonia-nct03742102. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"BEGONIA","arms":[{"description":"durvalumab + paclitaxel","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"durvalumab + paclitaxel + capivasertib","label":"Arm 2","type":"EXPERIMENTAL"},{"description":"durvalumab + paclitaxel + oleclumab","label":"Arm 5","type":"EXPERIMENTAL"},{"description":"durvalumab + trastuzumab deruxtecan","label":"Arm 6","type":"EXPERIMENTAL"},{"description":"durvalumab + datopotamab deruxtecan","label":"Arm 7","type":"EXPERIMENTAL"},{"description":"durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)","label":"Arm 8","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-02-26","type":"ESTIMATED"},"conditions":["Triple Negative Breast Neoplasms"],"enrollment":{"count":243,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","type":"DRUG"},{"name":"Capivasertib","type":"DRUG"},{"name":"Oleclumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Datopotamab deruxtecan","type":"DRUG"}],"last_update":"2026-08-04","lead_sponsor":"AstraZeneca","official_title":"A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-11-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Dose Limiting Toxicity (DLT) Events","timeFrame":"From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))"}],"references":[{"citation":"Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, Lord S, Armstrong J, Stewart R, Vukovic P, Denduluri N, Park YH. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. Nat Cancer. 2026 Jun;7(6):983-992. doi: 10.1038/s43018-026-01181-8. Epub 2026 Jun 8.","pmid":"42259988","type":"DERIVED"}],"start_date":{"date":"2018-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03742102"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/begonia-nct03742102"}